European Heart Journal Advance Access originally published online on April 4, 2008
European Heart Journal 2008 29(13):1644-1652; doi:10.1093/eurheartj/ehn133
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation
1 Electrophysiology and Pacing Unit, IRCCS Istituto Clinico Humanitas Rozzano-Milano, Via Manzoni 56, Rozzano, Milano IT-2089, Italy
2 Department of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Switzerland
3 Division of Cardiology, University Hospital Magdeburg, Magdeburg, Germany
4 Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, Unit of Cardiology, University and Spedali Civili, Brescia, Italy
5 Department of Cardiology, Heart and Diabetes Centre NRW, Bad Oeynhausen, Germany
6 Service of Biometry and Clinical Epidemiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Received 24 June 2007; revised 1 February 2008; accepted 10 March 2008; online publish-ahead-of-print 4 April 2008.
* Corresponding author. Tel: +39 0282244622, Fax: +39 0282244693, Email: maurizio.gasparini{at}humanitas.it
See page 1597 for the editorial comment on this article (doi:10.1093/eurheartj/ehn237)
Aims: To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients.
Methods and results: Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm (SR) and 243 (19%) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or prescribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up. During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per 100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57–1.42), P = 0.64 and 1.00 (0.60–1.66) P = 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P < 0.001). Adjusted hazard ratios of AVJ-abl vs. AF-Drugs was 0.26 [95% confidence interval (CI) 0.09–0.73, P = 0.010] for all-cause mortality, 0.31 (95% CI 0.10–0.99, P = 0.048) for cardiac mortality, and 0.15 (95% CI 0.03–0.70, P = 0.016) for HF mortality.
Conclusion: Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.
Key Words: Cardiac resynchronization therapy • Heart failure • Atrial fibrillation • Atrio-ventricular junction ablation
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Cardiac resynchronization therapy and atrial fibrillation. Do we have a final answer?
- Christophe Leclercq and Philippe Mabo
EHJ 2008 29: 1597-1599.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  P. W.X. Foley and F. Leyva Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of atrio-ventricular junction ablation in patients with permanent atrial fibrillation Eur. Heart J., September 1, 2008; 29(17): 2182 - 2182. [Full Text] [PDF]
|
|
|
|
|
|
C. Leclercq and P. Mabo Cardiac resynchronization therapy and atrial fibrillation. Do we have a final answer? Eur. Heart J., July 1, 2008; 29(13): 1597 - 1599. [Full Text] [PDF]
|
|